After being boxed in, for the past couple of weeks, Amgen’s (AMGN) stock finally outperformed. The firm was outperforming silently with regard to its financial results, sciences, technologies, pipeline products and multiple newly approved products drugs.
In the News
Amgen's Product AMG-510
Amgen announced new data from its ongoing Phase 1 study evaluating its unique cancer product AMG . . .